Drugs / melanoma helper peptide vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00118274 | Mar 2005 → Feb 2010 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00071981 | May 2005 → Aug 2011 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | melanoma helper peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00118274 ↗ |
| Known as | 6MHP | “Patients were vaccinated with 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) to stimulate CD8(+) T cells and were randomly assigned to receive...” PMID 21690475 ↗ Jun 2011 |
| Modality | Vaccine | “melanoma helper peptide vaccine (6HP)” NCT00071981 ↗ |
| Route | Subcutaneous | “melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC” NCT00071981 ↗ |